Estimating the annual risk of infection with Mycobacterium tuberculosis among adolescents in Western Kenya in preparation for TB vaccine trials by Nduba, V. (Videlis) et al.
RESEARCH ARTICLE Open Access
Estimating the annual risk of infection with
Mycobacterium tuberculosis among
adolescents in Western Kenya in
preparation for TB vaccine trials
Videlis Nduba1,2*, Anna H. van’t Hoog2,3, Annefleur de Bruijn2, Ellen M. H. Mitchell2,4, Kayla Laserson5 and
Martien Borgdorff2
Abstract
Background: Adolescents are a prime target group for tuberculosis (TB) vaccine trials that include prevention of
infection (POI). The BCG vaccine is given at birth and does not prevent TB infection. TB infection, a critical endpoint
for POI vaccine trials would need to be documented to estimate sample sizes in target populations.
Methods: Adolescents aged 12–18 years of age were enrolled in an area under continuous demographic
surveillance. A tuberculin skin test (TST) survey was conducted as part of a study on TB prevalence and incidence.
All adolescents got TSTs at enrolment and returned after 72 h for reading. A TST of ≥10 mm if HIV negative or ≥ 5
mm if HIV positive, was considered positive.
Results: Of 4808 adolescents returning for TST readings (96% of those enrolled), mean age was 14.4 (SD 1.9),
4518(94%) were enrolled in school and 21(0.4%) gave a previous history of tuberculosis. Among adolescents with
TST reactivity, the mean TST induration was 13.2 mm (SD 5.4). The overall prevalence of latent TB infection was
1544/4808 (32.1, 95% CI 29.2–35.1) with a corresponding annual risk of TB infection (ARTI) of 2.6% (95% CI 2.2–3.1).
Risk factors for a positive TST included being male (OR 1.3, 95% CI 1.2,1.5), history of having a household TB contact
(OR 1.5, 95% CI 1.2,1.8), having a BCG scar (OR 1.5,95% CI 1.2,1.8), living in a rural area (OR 1.4, 95% CI 1.1,1.9), and
being out of school (OR 1.8, 95% CI 1.4,2.3).
Conclusion: We conclude that the high TB transmission rates we found in this study, suggest that adolescents in
this region may be an appropriate target group for TB vaccine trials including TB vaccine trials aiming to prevent
infection.
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Background
Kenya ranks 10th out of 22 high TB burden countries glo-
bally [1]. The high prevalence of HIV in Kenya [1, 2] is a
major contributing factor to TB incidence. Siaya County in
Western Kenya has a high burden of tuberculosis and HIV
with a TB case notification rate of 400/100,000 [3] and HIV
prevalence of 15.1% [1].
Latent tuberculosis infection (LTBI) is the presence of
Mycobacterium tuberculosis (MTB) in the body without
signs and symptoms, or radiographic or bacteriologic
evidence of tuberculosis (TB) disease [4]. One method
to measure the trend of TB transmission is through re-
peated tuberculin surveys in order to estimate the trend
of the prevalence of tuberculous infection and annual
risk of tuberculous infection (ARTI). ARTI is used to
measure the effectiveness of TB control programs. In
addition, If TST conversion is a secondary endpoint for
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candidate vaccines preventing infection, ARTI estimates
may also be used to inform the sample size of such
trials.
Kenya has carried out several TST surveys to estimate
the ARTI. These surveys were standardized by targeting
primary school children aged 6–13 years and using the
same TST technique [5–7]. The surveys were conducted
in randomly selected districts and weighted for the
underlying population distribution based on the most re-
cent census. The ARTI estimates for Siaya district
(where our present study was conducted) were 0.36, 1.10
and 1.45% for the surveys conducted in 1986–1990,
1994–1996 and 2004–2007 respectively with a mean age
of 10 years in each sampled population indicating a ris-
ing ARTI over time [5–7].
Bacillus Calmette-Guerin (BCG), the TB vaccine given
at birth, has not been shown to reliably prevent pulmon-
ary tuberculosis in adolescents [8]. Adolescents may be
prime candidates to receive new more effective TB vac-
cines because they are entering an age of steeply rising
TB rates [9]. TB vaccine trials enrolling adolescents will
need to measure efficacy using several endpoints, includ-
ing TB disease incidence. Measuring the ARTI and the
prevalence of infection in preparation for TB vaccine tri-
als can give an indication of TB transmission in target
communities. In this study, we aimed to estimate the an-
nual risk of infection with MTB among 12–18 year olds.
Some of the interim results of this study have previously
been reported in an abstract at the Biennial infectious
disease conference, Nairobi Hospital Convention Centre,
Nairobi, Kenya, 2017.
Methods
Study design and sample size
The study area, Karemo Division with a population of
85,000 people, part of Siaya County is under a continu-
ous health and demographic surveillance system (HDSS)
[10]. The HDSS collects biannual data using household
surveys. In brief, the study area was divided into 17 clus-
ters of approximately equal population size. The clusters
were randomly selected to give each adolescent an equal
probability of participation. Eight out of 17 clusters were
used for enrolment. In each cluster, HDSS data was used
to identify households with adolescents; parents at these
households were then approached to have their children
participate in the study. The survey was conducted as
part of a study on TB prevalence and incidence which
used a prospective observational cohort design enrolling
adolescents aged 12–18 years [11].
Study procedures
Informed consent and clinical interviews
Parental consent was obtained at home by study staff
prior to inviting adolescents to a mobile field site where
minor assent was obtained prior to study participation.
During enrolment, standard social demographic data
were collected including age, sex, school enrolment
status, parental social economic status, parental mortal-
ity, recent migration, and urban or rural residence. In
addition, several clinical characteristics were collected
including history of immunization with BCG, history of
tuberculosis, BCG scar (we used the presence of a scar
to stratify BCG status), weight and height. Study proce-
dures have been described in more detail elsewhere [11].
The study received ethical approval of the Kenya Med-
ical Research Institute and the US Centres for Disease
Control and Prevention.
Tuberculin skin test and HIV testing
All enrolled adolescents were offered a tuberculin skin
test (TST) for LTBI after they provided a clinical history
and vital signs were recorded. The TST used 0.1 ml of
tuberculin purified protein derivative (PPD) containing
5TU (tuberculin units) RT23 with Tween 80 (Statens
Serum Institute, Copenhagen, Denmark) and was
injected intradermally into the middle dorsal region of
the right forearm using a disposable tuberculin syringe
and G.26 needle. Adolescents were offered a TST after
giving clinical history and getting vital signs recorded.
Adolescents returned after 72 h for the reading of their
TST results. Late TST readings were allowed up to a
maximum of 7 days. All adolescents were offered HIV
counselling and testing during the TST reading day.
Parental/ guardian consent and adolescent assent were
obtained prior to conducting HIV testing. Adolescents
identified with HIV were referred to HIV care and treat-
ment services at the Patient Support Centre at the Siaya
District Hospital or to the nearest accessible Patient
Support Centre.
The TST cut off we used as evidence for LTBI was
≥10mm in adolescents that did not have HIV or whose
HIV status was unknown and ≥ 5 mm in adolescents
with HIV [12].
Statistical analysis
Statistical analysis was performed using SAS 9.2 (SAS
Institute Inc., Cary, NC, US). A three point moving aver-
age was used on the TST induration data to look for
digit preference by observing differences in peaks be-
tween actual and smoothed data. The point prevalence
of LTBI and 95% confidence intervals were calculated
using survey procedures in SAS and adjusted for cluster-
ing. The prevalence of LTBI was estimated using the
cut-off method and mirror method [13]. The cut-off
method used the study defined cut-off of 10 mm. In the
mirror method, the mode of the distribution of those
with presumed tuberculous infection is derived from the
overall frequency distribution of TST reactions among
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the adolescents. Then, the total number of adolescents
with positive TST reactions was estimated as the sum of
the number of adolescents showing reaction sizes equal
to the mode and double the number of adolescents with
reaction sizes larger than the mode [13]. Bivariate ana-
lysis was used to determine significant associations
between various risk factors and a positive tuberculin
skin test. Factors significant at the p < 0.2 level were fur-
ther explored in a multivariate model using logistic
regression. ARTI was calculated with the formula
ARTI = 1-(1-prevalence of infection) 1/mean age [14].
Results
A total of 5004 adolescents aged 12–18 years were en-
rolled between August 2008 and August 2009 (Fig. 1).
All adolescents enrolled received tuberculin skin tests
(TST) and a total of 4808 (96.0%) came for their TST
readings and were included in the analysis. There was
no difference in socio demographic factors between
adolescents dropping after enrolment and before TST
readings and those that continued the study. Of the
4808 with TST readings, the mean age was 14.4 (SD
1.9), 2327 (48%) were female, the mean body mass index
(BMI) was 17.9 (SD 2.5), 4518 (94%) were currently en-
rolled in school, 4550 (95%) lived in a rural area, 1289
(26.8%) were orphaned, 861 (18%) had no BCG scar,
23(0.5%) were HIV positive, and 21(0.4%) gave a history
of previous tuberculosis (Table 1). There was no signifi-
cant difference in the baseline characteristics between
those who came back for TST readings and those that
failed to turn up [data not shown].
TST indurations
Of the 4808 adolescents with TST results, 4166 (86.7%)
were read within 4 days, 2762 (58%) did not have any in-
duration. Of the 3947 adolescents with a BCG scar, 2177
(55%) had no induration compared to 585/861 (86%) of
adolescents without a BCG scar. Among adolescents
with TST reactivity, the mean TST induration was 13.2
mm (SD 5.4). There was marked digit preference at 10
mm, 15 and 16mm and some digit avoidance at 13 mm
(Fig. 2). The smoothed data (three-point moving aver-
age) of all the adolescents showed a mode of 17 (Fig. 2).
Smoothed data for adolescents with and without a BCG
scar showed a mode of 17 and 18 respectively (Fig. 2).
Prevalence of infection and ARTI
Using the cut-off method, including one adolescent
with HIV with a TST of 5 mm, the overall prevalence
of LTBI was 1544/4808 (32.1, 95% CI 29.2–35.1) with
Fig. 1 Participant enrolment and tuberculosis skin testing
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a corresponding ARTI of 2.6% (95% CI 2.2–3.1).
Among adolescents with a BCG scar, the prevalence of
positive reactions was 33.5% (95% CI 30.3–36.8) with an
estimated ARTI of 2.7% (95% CI 2.2–3.2) and among
adolescents without a BCG scar, the prevalence of positive
reactions was 25.6% (95% CI 22.0–29.2) and the corre-
sponding ARTI 2.1% (95% CI 1.1–3.1) (Table 2). The
Mirror method suggested an ARTI of 2.2% (95% CI 1.7–
2.7) in those with and 2.1% (95% CI 1.1–3.1) for those
without a BCG scar.
Risk factors for tuberculous infection (LTBI)
Using the cut-off method, risk factors for a positive TST
result were being male (OR 1.3, 95% CI 1.2,1.5), history
of having a household TB contact (OR 1.5, 95% CI 1.2,
1.8), having a BCG scar (OR 1.5,95% CI 1.2,1.7) living in
a rural area (OR 1.4, 95% CI 1.1,1.9), and being out of
school (OR 1.8,1.4,2.3). The mirror method identified
being male (OR 1.4, 95% CI 1.2,1.7) and having a house-
hold TB contact (OR 1.6, 95% CI 1.2,2.1) as risk factors
for a positive TST (Table 3).
Table 1 Demographic characteristics of 4808 adolescents undergoing tuberculin skin testing in Kenya, 2008–2009
Characteristic Category All (4808)
Tuberculin skin test (TST) Reactive 1544 (32.1%)
Non reactive 3264 (67.9%)
Sex Female 2327 (48.4%)
Male 2481 (51.6%)
School going Yes 4518 (94.0%)
No 290 (6.0%)
HIV status Positive 23 (0.5%)
Negative 1985 (41.3%)
Unknown 2165 (45.0%)
Residence Rural 4550 (94.6%)
Urban 258 (5.4%%)
Previous TB Yes 21 (0.4%)
No 4787 (99.6%)
History of TB contact Yes 138 (2.9%)
No 4670 (97.1%)
Deceased parents One parent deceased or both alive 3519 (73.2%)
Both deceased 1289 (26.8%)
Socio economic status Upper class 1582 (32.9%)
Middle class 1636 (34.0%)
Lower class 1590 (33.1%)
Fig. 2 A three point moving average of TST indurations for all adolescents with and without a BCG scar.*BCG scar present 2177/3947(55.2%) had
0mm induration. *BCG scar absent 585/861 (86%) had 0mm induration
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All risk factors identified during bivariate analysis
remained independently associated with a positive TST
in multivariate analysis (Table 3).
Discussion
Our study showed an ARTI of 2.6% (95% CI 2.2–
3.1) with the cut-off method and 2.2% (95% CI 1.8–
2.6) with the mirror method, both of which are more
than double the expected based on serial TST sur-
veys among children aged 10 years in the same area
that reported an ARTI of 1.1% [5–7]. This suggests
that TB transmission may be more intense among
adolescents than among young children. This is con-
sistent with findings by Dodd et al. who suggested
estimates of TB infection based on surveys in chil-
dren may underestimate infection incidence in adults
[15]. A higher risk of infection among adolescents
than among children of primary school age has also
been reported elsewhere [16, 17]. In addition, a
golden age has previously been described where the
incidence of infection goes down after 5 years of age
and begins to rise in adolescence [18].
Table 2 ARTI estimates and prevalence of infection presented for all adolescents, those with and without a BCG scar
N Mean
age
(years)
≥ 10mmb Mirror method 17mma
P ARTI CI (95%) P ARTIc CI (95%)
All 4808 14.4 32.1% 2.6% (2.2,3.1) 27.6% 2.2% (1.8,2.6)
BCG scar 3947 14.4 33.5% 2.7% (2.2,3.2) 27.8% 2.2% (1.7,2.7)
BCG scar absent 859 14.2 25.6% 2.1% (1.1,3.1) 27.0% 2.1% (1.1,3.1)
CI 95% Confidence interval
aThe total number of adolescents with true reactions was calculated by adding the number of adolescents showing reaction sizes equal to the mode to double
the number with reaction sizes larger than the mode to determine the numerator
bThe Cut-off for HIV+ was ≥5mm
cARTI formula =1-(1-prevalence of infection) 1/mean age
Table 3 Risk factors for a positive tuberculin skin test (TST) for the 10 mm cut-off method and the 17 mm mirror method
Risk Factor Tuberculin skin test > = 10 mm n =
4808
Multivariate Tuberculin skin test > = 17 mm n =
4808
Multivariate
Negative Positive OR, 95%
CI
OR, 95% CI Negative Positive OR, 95%
CI
OR, 95% CI
Sex Female 1650 677/2327
(29.1%)
1 2076 251/2327
(10.8%)
1
Male 1614 867/2481
(34.9%)
1.3 (1.2,
1.5)
1.3 (1.2,1.5) 2129 352/2481
(14.2%)
1.4 (1.2,
1.6)
1.4 (1.2,1.7)
History of a house hold TB
contact
Yes 224 150/374 (40.1%) 1.5 (1.2,
1.8)
1.5(1.2,1.8) 119 19/138 (13.8%) 1
No 3040 1394/4434
(31.4%)
1 4086 584/4670
(12.5%)
1.6 (1.2,
2.1)
1.6(1.2,2.1)
Previous TB Yes 15 6/21 (28.6%) 1 18 3/21 (14.3%) 1
No 3232 1528/4787
(32.1%)
0.8 (0.3,
2.1)
4163 597/4760
(12.5%)
1.2 (0.4,
3.7)
BCG Scar Yes 2623 1324/3947
(33.5%)
1.3 (1.2,
1.7)
1.5 (1.3,1.8) 3450 497/3947
(12.6%)
1.0 (0.8,
1.3)
1.0 (0.8,1.3)
No 641 220/861 (25.6%) 1 753 106/859 (12.3%) 1
Residence Urban 189 69/258 (26.7%) 1 231 27/258 (10.5%) 1
Rural 3075 1475/4550
(32.4%)
1.2 (1.0,
1.5)
1.4 (1.1,1.9) 3974 576/4550
(12.7%)
1.2 (0.8,
1.9)
1.2(0.8,1.9)
School going Yes 3103 1415/4518
(31.3%)
1 3960 558/4518
(12.4%)
1
No 161 129/290 (44.5%) 1.8(1.4,2.2) 1.8 (1.4,2.3) 245 45/290 (15.5%) 1.3 (0.9,
1.8)
1.3(1.0,1.8)
Orphaned Yes 1136 585/1721
(34.0%)
1 1474 247/1721
(14.4%)
1
No 2128 959/3087
(31.1%)
1.1 (1.0,
1.3)
1.1(1.0,1.3) 2731 356/3087
(11.5%)
1.3 (1.1,
1.5)
1.3(1.1,1.5)
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There are methodological challenges to measuring
ARTI in adolescents, including the influence of previous
BCG vaccination and exposure to environmental myco-
bacteria on TST results [19, 20]. Even though TST is a
relatively inexpensive test, it has low specificity causing
false positives in patients with history of BCG vaccin-
ation and environmental mycobacteria exposure [21]. In
this study, BCG vaccination status was indeed associated
with a positive TST result in the cut-off method, but the
mirror method appeared to have eliminated this bias.
ARTI was high both in those with and without a BCG
scar, using either the cut-off or mirror method. Exposure
to environmental mycobacteria appears not to have been
a major factor given the low frequency of intermediate
reactions (5–9 mm) and the similar prevalence estimate
using the cut-off method and mirror method in those
without BCG vaccination scar. Even though an inter-
feron gamma release assay (IGRA) was not performed to
ascertain TB infection, excellent concordance between
tuberculin skin test and IGRA conversion rates has been
previously demonstrated [22].
Risk factors for a positive TST were similar to those
reported in studies elsewhere, including male sex [9] and
having a BCG scar [23]. The higher risk of TB infection
in males might be related to older boys having more
contact with adult men among whom TB prevalence is
higher, as suggested by Dodd [15]. Although only a small
proportion (6%) of adolescents in this study were not
currently enrolled in school, they were significantly more
likely to have a positive TST compared to in school
youth 45 and 31% respectively (OR 1.8, 95% CI 1.1, 2.9).
However, this subgroup may be a good target population
for intensified case finding and prevention. The majority
of adolescents enrolled were of rural residence (94.6%)
and this was associated with a positive TST also in a
multivariate model. However, the difference was not
large (32% versus 27%). As expected history of a house-
hold contact was strongly predictive of a positive TST
40.1% versus 31.4%). Previous TB surprisingly was not
associated with a positive TST, but numbers were small.
Having both parents deceased was associated with a
positive TST (34% versus 31%)). The study area has a
high HIV prevalence of 15.1% [2] and many deaths
among parents are likely to have been due to HIV/AIDS,
which in this area is strongly associated with tubercu-
losis indicating a higher risk of LTBI in orphaned
children before their parents died.
The ARTI estimates are derived from a point prevalence
estimate and repeated TST surveys would need to be con-
ducted to see how this correlates with the incidence of in-
fection and age associated risks of infection [16, 17].
While BCG had some influence on TST reading results
using the cut-off method, this was no longer the case
using the mirror method. Digit preference was corrected
by smoothing, though might be further reduced in the fu-
ture by further strengthening training and supervision.
Preventing TB disease instead of infection has been the
key goal of vaccine development [24]. Epidemiological
and mathematical modelling studies have shown a pre-in-
fection vaccine would have a high level impact on TB dis-
ease control [24]. A pre-infection vaccine will require
choice of an age range where the risk of infection rises but
before majority of the age group becomes infected. Ado-
lescents are an important group for vaccination against
TB because while TB incidence is relatively low in the age
group 5–14 years, it rises rapidly in adolescence [25]. In
our study majority of adolescents (67.9%) were TST nega-
tive indicating this would be a good age group to target
for prevention of infection vaccine studies. We have re-
ported on the incidence of tuberculosis in adolescents
elsewhere [26]. The incidence of TB addresses the sample
sizes needed for TB vaccine efficacy trials preventing dis-
ease; whether primary disease or reactivation from previ-
ous TB infection. Because of difficulties in having a
human challenge model with tuberculosis, a pathway to
understanding the immune mechanisms of protection
against tuberculosis with new vaccines would be to con-
duct prevention of infection with M.tuberculosis studies as
a marker of biologic impact [24]. The studies will need to
take into account the huge burden of non tuberculous
mycobacteria (NTM) infection in this population includ-
ing using interferon gamma release assays to disciminate
M.TB infection from NTM infection [11]. Since infection
with M.tuberculosis happens much more often than TB
disease, the trials will be much smaller and trial results
would be obtained much sooner allowing a read-out on a
TB vaccine candidate’s likely efficacy before doing larger
scale efficacy studies.
Conclusion
We conclude that the high TB transmission rates we
found in this study, suggest that adolescents in schools
in this region may be an appropriate target group for TB
vaccine trials including TB vaccine trials aiming to pre-
vent infection. Out of school adolescents might be
harder to enroll and follow up for TB incidence.
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